1. Omics underpins novel clues on VDR chemoprevention target in breast cancer
- Author
-
Gennaro Citro, Sabrina Strano, Giuseppe Carrubba, Paola Muti, Giovanni Blandino, Elisabetta Falvo, Barbara Benassi, Sergio Galanti, and Raffaela Santoro
- Subjects
Antineoplastic Agents ,Breast Neoplasms ,Pharmacology ,Malignancy ,Bioinformatics ,Biochemistry ,Calcitriol receptor ,Breast cancer ,Genetics ,medicine ,Animals ,Humans ,Raloxifene ,Vitamin D ,Molecular Biology ,Polymorphism, Genetic ,business.industry ,Gene Expression Profiling ,Cancer ,Genomics ,medicine.disease ,Omics ,Cell Transformation, Neoplastic ,Molecular Medicine ,Receptors, Calcitriol ,Identification (biology) ,Female ,business ,Tamoxifen ,Biotechnology ,medicine.drug - Abstract
Breast cancer is the commonest form of female malignancy among women in Western countries. The advent of genomic technologies has enhanced the diagnosis and the biological classification of such pathology. It has been demonstrated that cancer takes many years to be fully established. This long dormancy could represent a potential window for intervening with chemoprevention studies. Cancer chemoprevention is by definition the use of natural, synthetic, or biological chemical agents to reverse, suppress, or delay the genetic or other alterations that culminate in the appearance of the tumor phenotype. An important step for the success of chemoprevention is the identification of molecularly targeted agents to prevent cancer development. Currently, only two chemoprevention agents, raloxifene and tamoxifen, are used in clinical practice to prevent breast cancer. In this review, we will mainly focus on: (1) the application of genomic technologies for the identification and validation of molecular targets for chemoprevention; (2) the role of vitamin D and its cognate receptor VDR (vitamin D receptor) as a model for the molecularly targeted chemoprevention of breast cancer.
- Published
- 2011